1 / 4

Comorbid Migraine Does Not Affect Efficacy of Milnacipran in Management of Fibromyalgia

Comorbid Migraine Does Not Affect Efficacy of Milnacipran in Management of Fibromyalgia. Placebo. Milnacipran 100 mg/day. Milnacipran 200 mg/day. Proportion of Patients Achieving a ≥30% Reduction in Pain Scores at Week 12 of Stable Dose Treatment. PED Pain Responders. ***. ***. ***. ***.

reba
Télécharger la présentation

Comorbid Migraine Does Not Affect Efficacy of Milnacipran in Management of Fibromyalgia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Comorbid Migraine Does Not Affect Efficacy of Milnacipran in Management of Fibromyalgia

  2. Placebo Milnacipran 100 mg/day Milnacipran 200 mg/day Proportion of Patients Achieving a ≥30% Reduction in Pain Scores at Week 12 of Stable Dose Treatment PED Pain Responders *** *** *** *** % of Patients n=545 n=491 n=318 n=232 n=234 n=159 *** P≤0.001 vs placebo PED= Patient Experience Diary

  3. Placebo Milnacipran 100 mg/day Milnacipran 200 mg/day Proportion of Patients Achieving a PGIC Score of “Very Much Improved” or “Much Improved” at Week 12 of Stable Dose Treatment PGIC Responders *** *** *** *** % of Patients n=566 n=507 n=344 n=239 n=251 n=175 *** P<0.001 vs placebo PGIC= Patient Global Impression of Change

  4. Placebo Milnacipran 100 mg/day Milnacipran 200 mg/day Percentage of 2-Measure Composite Responders at Week 12 of Stable Dose Treatment 2-Measure Composite Responders *** *** *** ** % of Patients n=542 n=490 n=316 n=230 n=239 n=159 **P<0.01; *** P<0.001 vs placebo

More Related